You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
NEW YORK (GenomeWeb News) – Epic Sciences today announced it has completed its Series B financing round raising $13 million.
Germany's Curetis has initiated a prospective clinical trial in the European Union for its Unyvero molecular testing system and P50 Pneumonia test cartridge, the company said in February.
By Ben Butkus
NEW YORK (GenomeWeb News) – Curetis today announced its Series A financing round has increased by €9.6 million ($13.3 million) bringing the total amount raised in the round to €34.1 million.
According to founder and CEO Scott Tanner, the funds will go primarily toward ramping up production of CyTOF instruments, reagent production, and the establishment of a global sales and service team.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.